BioNxt Solutions Inc. (CSE:BNXT)

Canada flag Canada · Delayed Price · Currency is CAD
0.8700
+0.0100 (1.16%)
Oct 9, 2025, 3:59 PM EDT
1.16%
Market Cap105.42M
Revenue (ttm)21.66K
Net Income (ttm)-6.04M
Shares Out121.18M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume74,550
Average Volume130,231
Open0.8700
Previous Close0.8600
Day's Range0.8500 - 0.8700
52-Week Range0.2250 - 1.0600
Beta1.61
RSI51.69
Earnings DateNov 28, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a... [Read more]

Sector Healthcare
Founded 2017
Employees 20
Stock Exchange Canadian Securities Exchange
Ticker Symbol BNXT
Full Company Profile

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial Statements

News

There is no news available yet.